BenevolentAl Therapeutics Pipeline and Triage

BEN-8744: Potent activity demonstrated in both UC & CD patient ex-vivo colon biopsies² Individual donor response: UC and CD biopsies Ulcerative colitis donor 1500- 15000- Demonstrated inhibition of proinflammatory cytokine release (IL-6/IL-8) from individual UC and CD patient biopsy samples, comparable to corticosteroids Indicative of a robust anti-inflammatory response with BEN-8744 BEN-8744 has now progressed into preclinical development and a Clinical Trial Application (CTA) is scheduled Q4 2022 ⚫ First-in-Human (SAD/MAD) clinical studies will commence early 2023 ⚫ Subsequently supporting a Ph2a clinical study in Ulcerative Colitis, together with a follow-on clinical study in Crohn's Disease 1SAD/MAD- Single Ascending Dose, Multiple Ascending Dose 2 Company internal drug programme data IL6 pg/ml 0- 1000- 500- DMSO 0.1% Prednisolone 1uM BEN-8744 0.01uM BEN-8744 0.1uM Crohn's disease donor IL6 pg/ml 2500- 2000- 1500- 1000- 500- 0- DMSO 0.1% Prednisolone 1uM BEN-8744 0.01uM BEN-8744 0.1uM IL-6 BEN-8744 1UM IL-6 BEN-8744 1uM IL8 pg/ml IL8 pg/ml IL-8 10000 5000- DMSO 0.1%" Prednisolone 1uM BEN-8744 0.01uM BEN-8744 0.1uM BEN-8744 1uM 100000- IL-8 50000- 0. DMSO 0.1% Prednisolone 1uM BEN-8744 0.01uM ///// BEN-8744 0.1uM BEN-8744 1uM Benevolent 43

View entire presentation